Genzyme
4
190M
4
0.10
3
3
- Areas of investment
Summary
In 1981 was created Genzyme, which is appeared as Corporate Investor. The fund was located in North America if to be more exact in United States. The leading representative office of defined Corporate Investor is situated in the Cambridge.
This Genzyme works on 46 percentage points more the average amount of lead investments comparing to the other organizations. The usual things for fund are deals in the range of more than 100 millions dollars. The fund is constantly included in less than 2 investment rounds annually. The important activity for fund was in 2008. The real fund results show that this Corporate Investor is 55 percentage points more often commits exit comparing to other companies. The increased amount of exits for fund were in 2017.
The fund has no exact preference in a number of founders of portfolio startups. When startup sums 1 or 3 of the founder, the probability for it to get the investment is little. For fund there is a match between the location of its establishment and the land of its numerous investments - United States. Among the most popular portfolio startups of the fund, we may highlight Voyager Therapeutics, Peptimmune, Alnylam Pharmaceuticals. Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund. Among the most popular fund investment industries, there are Pharmaceutical, Genetics.
The fund was created by George Whitesides, Sheridan Snyder.
The typical case for the fund is to invest in rounds with 4 participants. Despite the Genzyme, startups are often financed by MPM Capital, Vanguard Ventures, Sofinnova Investments. The meaningful sponsors for the fund in investment in the same round are MPM Capital, Vanguard Ventures, Sofinnova Investments. In the next rounds fund is usually obtained by MPM Capital, Silicon Valley Bank, New Enterprise Associates.
Investments analytics
Analytics
- Total investments
- 4
- Lead investments
- 3
- Exits
- 3
- Rounds per year
- 0.10
- Investments by industry
- Biotechnology (4)
- Health Care (3)
- Pharmaceutical (3)
- Medical (2)
- Genetics (1) Show 3 more
- Investments by region
-
- United States (4)
- Peak activity year
- 2015
- Number of Minotaurs
- 1
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 16
- Avg. valuation at time of investment
- 5M
- Group Appearance index
- 0.50
- Strategy success index
- 0.62
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Peptimmune | 07 Jun 2006 | Biotechnology, Medical, Pharmaceutical | Late Stage Venture | 12M | United States, Massachusetts, Cambridge |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.